Regenxbio Inc (RGNX)
10.80
+0.12
(+1.12%)
USD |
NASDAQ |
Sep 27, 16:00
10.81
+0.01
(+0.09%)
After-Hours: 20:00
Regenxbio SG&A Expense (Annual): 88.49M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 88.49M |
December 31, 2022 | 85.28M |
December 31, 2021 | 79.33M |
December 31, 2020 | 63.82M |
December 31, 2019 | 51.82M |
December 31, 2018 | 36.85M |
Date | Value |
---|---|
December 31, 2017 | 27.23M |
December 31, 2016 | 23.59M |
December 31, 2015 | 11.91M |
December 31, 2014 | 3.851M |
December 31, 2013 | 5.474M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
51.82M
Minimum
2019
88.49M
Maximum
2023
73.75M
Average
79.33M
Median
2021
SG&A Expense (Annual) Benchmarks
Sarepta Therapeutics Inc | 481.87M |
Pfizer Inc | 14.77B |
Catalyst Pharmaceuticals Inc | 133.71M |
EyePoint Pharmaceuticals Inc | 51.79M |
Cassava Sciences Inc | 16.53M |